Provided by Tiger Fintech (Singapore) Pte. Ltd.

Crinetics Pharmaceuticals Inc.

30.64
-0.6500-2.08%
Volume:59.89K
Turnover:1.85M
Market Cap:2.87B
PE:-8.03
High:31.35
Open:31.35
Low:30.54
Close:31.29
Loading ...

Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Veracyte (VCYT) and Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
12 May

Piper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
09 May

Earnings Flash (CRNX) Crinetics Pharmaceuticals Q1 Loss $1.04 Vs. FactSet Est. $0.94 Loss

MT Newswires Live
·
09 May

Earnings Flash (CRNX) Crinetics Pharmaceuticals Q1 Revenue $361,000 Vs. FactSet Est. $100,000

MT Newswires Live
·
09 May

Crinetics Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Crinetics reports Q1 EPS ($1.04), consensus (95c)

TIPRANKS
·
09 May

Crinetics Pharmaceuticals Q1 EPS $(1.04) Misses $(0.93) Estimate, Sales $361.00K Beat $90.91K Estimate

Benzinga
·
09 May

Crinetics Pharmaceuticals Reports Q1 2025 Results: Net Loss Widens to $96.8M, Revenues Decline to $0.4M

Reuters
·
09 May

BRIEF-Crinetics Pharmaceuticals Q1 Net Income USD -96.774 Million

Reuters
·
09 May

Crinetics Pharmaceuticals Inc: Cash Anticipated to Provide Runway Into 2029

THOMSON REUTERS
·
09 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

BRIEF-Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
11 Apr

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Apr

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly

Reuters
·
28 Mar

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug

MT Newswires Live
·
28 Mar

Crinetics Pharmaceuticals Announces European Medicines Agency (Ema) Validation of Marketing Authorization Application (Maa) and Orphan Drug Designation (Odd) for Paltusotine in Acromegaly

THOMSON REUTERS
·
28 Mar

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

GlobeNewswire
·
28 Mar

U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences

Reuters
·
26 Mar

BUZZ-Stifel initiates Crinetics Pharma with 'buy' on FDA approval prospects

Reuters
·
25 Mar

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target

MT Newswires Live
·
25 Mar